{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:01:53Z","timestamp":1768464113512,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013298","name":"Sociedad Espa\u00f1ola de Reumatolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.semarthrit.2021.11.010","type":"journal-article","created":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T01:06:24Z","timestamp":1641085584000},"page":"151944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: Systematic review"],"prefix":"10.1016","volume":"52","author":[{"given":"Marina","family":"Salido Olivares","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Est\u00edbaliz","family":"Loza Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.semarthrit.2021.11.010_bib0001","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.medcli.2011.06.020","article-title":"[Uveitis diagnosis characterization at a referral centre in the area of Barcelona, Spain]","volume":"138","author":"Lloren\u00e7 Bell\u00e9s","year":"2012","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.11.010_bib0002","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1076\/ocii.10.4.263.15592","article-title":"Uveitis: a global perspective","volume":"10","author":"Chang","year":"2002","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.11.010_bib0003","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.11.010_bib0004","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.11.010_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","article-title":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"47","author":"Cantini","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.11.010_bib0006","first-page":"220","article-title":"Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis","volume":"155","author":"Espinosa","year":"2020","journal-title":"Med Clin (Barc)"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.11.010_bib0007","first-page":"552","article-title":"Cordero-Coma M. Treatment recommendations for non-infectious anterior uveitis","volume":"149","author":"Espinosa","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.semarthrit.2021.11.010_bib0008","first-page":"i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical research ed)"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.11.010_bib0009","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10792-010-9372-1","article-title":"Effects of infliximab in the treatment of refractory posterior uveitis of Beh\u00e7et's disease after withdrawal of infusions","volume":"30","author":"Ad\u00e1n","year":"2010","journal-title":"Int Ophthalmol"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.11.010_bib0010","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/09273948.2013.779727","article-title":"Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Beh\u00e7et disease treated with infliximab","volume":"21","author":"Al Rashidi","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.11.010_bib0011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00417-016-3497-5","article-title":"Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis","volume":"255","author":"Breitbach","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.semarthrit.2021.11.010_bib0012","article-title":"Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Beh\u00e7et\u2019s Uveitis: customizing Therapy according to the Clinical Features","author":"De Simone","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"5","key":"10.1016\/j.semarthrit.2021.11.010_bib0013","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-013-2372-6","article-title":"Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients","volume":"33","author":"De Stefano","year":"2014","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.semarthrit.2021.11.010_bib0014","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10384-013-0283-3","article-title":"Clinical course of patients with Beh\u00e7et\u2019s uveitis following discontinuation of infliximab therapy","volume":"58","author":"Kawaguchi","year":"2014","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.semarthrit.2021.11.010_bib0015","article-title":"Clinical Follow-up of Patients with Beh\u00e7et Uveitis after Discontinuation of Infliximab Therapy","author":"K\u00f6se","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"5","key":"10.1016\/j.semarthrit.2021.11.010_bib0016","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3899\/jrheum.200300","article-title":"Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Beh\u00e7et Disease: national Study of 103 White Patients","volume":"48","author":"Mart\u00edn-Varillas","year":"2021","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.11.010_bib0017","first-page":"592","article-title":"Low dose etanercept treatment for maintenance of clinical remission in ankylosing spondylitis","volume":"34","author":"Park","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.semarthrit.2021.11.010_bib0018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/09273948.2013.812222","article-title":"Recurrence of uveitis after discontinuation of infliximab","volume":"22","author":"Shakoor","year":"2014","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"9","key":"10.1016\/j.semarthrit.2021.11.010_bib0019","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Beh\u00e7et\u2019s Disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"issue":"39","key":"10.1016\/j.semarthrit.2021.11.010_bib0020","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3748\/wjg.v13.i39.5238","article-title":"Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up","volume":"13","author":"Caviglia","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.semarthrit.2021.11.010_bib0021","doi-asserted-by":"crossref","first-page":"e00452","DOI":"10.1016\/j.heliyon.2017.e00452","article-title":"REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients","volume":"3","author":"Gonz\u00e1lez-\u00c1lvaro","year":"2017","journal-title":"Heliyon"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.11.010_bib0022","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Oxford, England)."},{"issue":"4","key":"10.1016\/j.semarthrit.2021.11.010_bib0023","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/bjophthalmol-2013-303935","article-title":"Immunomodulatory therapy with tumour necrosis factor \u03b1 inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results","volume":"98","author":"Doycheva","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.11.010_bib0024","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s10384-010-0824-y","article-title":"Intraocular surgery in patients receiving infliximab therapy for Beh\u00e7et disease","volume":"54","author":"Sakai","year":"2010","journal-title":"Jpn. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.semarthrit.2021.11.010_bib0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000329190","article-title":"Clinical Course before and after Cataract and Glaucoma Surgery under Systemic Infliximab Therapy in Patients with Beh\u00e7et\u2019s Disease","volume":"2","author":"Nishida","year":"2011","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.semarthrit.2021.11.010_bib0026","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1546-0096-11-16","article-title":"Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-\u03b1 therapy in childhood chronic uveitis","volume":"11","author":"Simonini","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.11.010_bib0027","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr Med Res Opin"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221002274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221002274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:08:53Z","timestamp":1758733733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221002274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":27,"alternative-id":["S0049017221002274"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: Systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151944"}}